retatrutide peptide clinical data Since January 2026, there have been six cases of acute liver toxicity associated with unapproved products labelled in Australia. These toxic effects may be linked to a contaminant in the retatrutide peptide clinical data The

Helmstdter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S, Pawelke F, Kus K, Krller-Schn S, Oelze M

However, these rules tend to relax when there is a shortage of a specific drug

It is not for people with type 1 diabetes or diabetic ketoacidosis

Anti-obesity medications are revolutioninising weight management Anti-obesity medications are placing new demands on the global food industry

In light of hypocalcemia in COVID-19 patients and its association with hypoparathyroidism (40), we detected significant levels of the anti-CaSR antibody (calcium receptor) in LC cohort ( Figure 6K )

These agents, known for their dual impact on both immune modulation and metabolic improvement, offer a unique therapeutic potential in managing immune-mediated inflammatory diseases ( 3.2 GLP-1RAs in psoriatic arthritis The therapeutic landscape of PsA is currently dominated by targeted agents that inhibit key inflammatory pathways, including TNF inhibitors (e.g., adalimumab, etanercept), IL17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and Janus kinase (JAK) inhibitors such as upadacitinib and tofacitinib ( Several studies have reported an inverse relationship between BMI and therapeutic efficacy, indicating that obesity may attenuate clinical responses to biologic disease modifying anti-rheumatic drugs (bDMARDs)